MESA LABS DECLARES QUARTERLY DIVIDEND
Mesa Laboratories has declared a regular quarterly dividend of $0.16 per share, payable on September 15, 2020 to shareholders of record as of August 31, 2020.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Mesa Laboratories has declared a regular quarterly dividend of $0.16 per share, payable on September 15, 2020 to shareholders of record as of August 31, 2020. This payment reflects the company's commitment to returning value to shareholders. Mesa Labs operates in critical sectors like pharmaceuticals and healthcare, focusing on quality control solutions through its four divisions. Investors should note potential risks as the company navigates post-pandemic challenges and competition in the market.
Positive
- Declared quarterly dividend of $0.16 per share, indicating financial stability and commitment to shareholders.
Negative
- Potential risks from economic conditions and competition, affecting growth and cash flow.
Details
News Market Reaction – MLAB
The recorded move for MLAB in the trading session of this news was +2.49%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Lakewood, CO, July 06, 2020 (GLOBE NEWSWIRE) -- - Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa Labs” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of
About Mesa Laboratories, Inc.
Mesa Labs is a global technology innovator committed to solving some of the most critical quality control challenges in the pharmaceutical, healthcare, industrial safety, environmental and food and beverage industries. Mesa Labs offers products and services through four divisions (Sterilization and Disinfection Control, Biopharmaceutical Development, Instruments and Continuous Monitoring) to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world.
Forward Looking Statements
This press release may contain information that constitutes forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our historical experience and present expectations or projections. Forward-looking statements include statements relating to revenues and growth, operating results, profit margin pressure, industry conditions, economic conditions, demand, competition, the effects of additional actions taken to become more efficient or lower costs, risks related to the integration of acquired businesses, changes in legal and regulatory matters, the ability to generate additional cash flow, and the duration and impact of the COVID-19 pandemic and the myriad of its effects on our business including related decreases in customer demand and spending, and any events or developments that we expect or anticipate will occur in the future. Generally, the words “expect,” “seek,” “anticipate,” “intend,” “plan,” “believe,” “could,” “estimate,” “may,” “target,” “project,” and similar expressions identify forward-looking statements. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. These statements are based upon current information and expectations. Actual results may differ materially from those estimated or anticipated as a result of these risks and unknowns or other risks and uncertainties. For additional information concerning these and other risks and uncertainties that could affect these statements, and the our business, see our Annual Report on Form 10-K for the year ended March 31, 2020, as well as other risks and uncertainties detailed from time to time in our reports on Forms 10-Q and 8-K subsequently filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof, to provide any updates, or to reflect the occurrence of future events.
For more information about the Company, please visit its website at www.mesalabs.com
CONTACT: Gary Owens; President and CEO, or John Sakys; CFO, both of Mesa Laboratories, Inc., +1-303-987-8000
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.